Oppenheimer analyst Kevin DeGeeter lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $33.00 (from $43.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE